Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-beta7 integrin monoclonal antibody. Etrolizumab is specific targeting of the beta7 subunit of alpha4beta7 and alphaEbeta7 integrins with Ki values of 18 nM and 1800 pM for Human alpha4beta7 and Human alphaEbeta7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD).
Reinheit:
99.0%
CAS Nummer:
[1044758-60-2]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten